Small molecules from microbes known as `natural products' have been an important source of clinically- approved drugs and cell biological probes, and developing new strategies for their discovery will expand the stream of natural products entering compound libraries at the NIH and elsewhere. Using a bioinformatic algorithm we recently developed to identify natural product-encoding gene clusters in microbial genome sequences, we have found numerous gene clusters in bacteria from a surprising location: the human microbiome. Herein, we propose to use a combination of chemistry, genetics, and bioinformatics to isolate, purify, and solve the structures of three classes of molecules from human gut and oral bacteria. This project will lay the groundwork for a larger effort to identify and characterize natural products from the human microbiome. There are three reasons why identifying natural products from the human microbiome should be a priority: 1) Underexplored ecological niches and bacterial phyla usually yield new natural products. 2) Natural products from the human microbiome are likely to have important biological activities, and are unlikely to be toxic to humans. 3) Computational searches for new natural products have become increasingly fruitful, and the Human Microbiome Project will provide a wealth of sequence data for human-associated bacteria. Not only will our efforts uncover natural products with unusually important biological activities, they will also validate the human microbiome as a new source of natural products and enable future studies of the molecular basis of interactions between humans and their microbiome. While this proposal is focused on identifying three classes of molecules from gut and oral bacteria, our long-term goal is to lay the groundwork for systematizing a computational search for new natural products from the human microbiome. Our efforts are organized into three Specific Aims:
Aim 1 : Identify and characterize the products of a family of NRPS gene clusters from gut bacteria. We have identified a family of >50 NRPS gene clusters that stands out for two reasons: 1) One or more of these gene clusters is present at a high level in 90% of healthy human subjects, making this one of the most widely distributed gene cluster families in the human population. 2) This family is only found in gut-dwelling bacterial species, raising the possibility that it plays an important biological role in the context of gut colonization.
Aim 2 : Identify and characterize the products of a family of NRPS and NRPS/PKS gene clusters from oral strains of Streptococcus. By analyzing the genome sequences of 285 oral isolates of Streptococcus, we have found that the major genetic differences among strains of these species are 14 biosynthetic gene clusters that occupy up to 8% of the genome. Metagenomic and metatranscriptomic analyses suggest that of these gene clusters, eight are large (up to 12- module) NRPS, PKS, and NRPS/PKS hybrids; all are widely distributed in the human population, and most are actively transcribed on teeth.
Aim 3 : Identify and characterize the products of a family of oligosaccharide gene clusters from Bacteroides. The largest family of biosynthetic gene clusters in the human microbiome, which are responsible for producing Bacteroides capsular polysaccharides, is underexplored. These molecules are present at high abundance in the gut and are known to have specific ligand-receptor interactions that modulate the host immune response.

Public Health Relevance

Natural products ? small molecules from microbes ? have been a primary source of clinically-used antibiotics, antifungals, anticancer agents, immunosuppressants, and other drugs. This proposal describes new approaches to discovering and characterizing natural products from an unusual source: human-associated microbes. Identifying and characterizing these molecules will not only lead to a greater understanding of the connection between the human microbiome and human disease, it will also lay the groundwork for a larger effort to discovery biologically active small molecules from the human microbiome.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK110174-04
Application #
9538720
Study Section
Synthetic and Biological Chemistry B Study Section (SBCB)
Program Officer
Karp, Robert W
Project Start
2016-09-21
Project End
2020-07-31
Budget Start
2018-08-01
Budget End
2019-07-31
Support Year
4
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Stanford University
Department
Biomedical Engineering
Type
Schools of Medicine
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94304
Fischbach, Michael A (2018) Microbiome: Focus on Causation and Mechanism. Cell 174:785-790
Chen, Y Erin; Fischbach, Michael A; Belkaid, Yasmine (2018) Skin microbiota-host interactions. Nature 553:427-436
Jacobson, Amy N; Choudhury, Biswa P; Fischbach, Michael A (2018) The Biosynthesis of Lipooligosaccharide from Bacteroides thetaiotaomicron. MBio 9:
Ridaura, Vanessa K; Bouladoux, Nicolas; Claesen, Jan et al. (2018) Contextual control of skin immunity and inflammation by Corynebacterium. J Exp Med 215:785-799
Skye, Sarah M; Zhu, Weifei; Romano, Kymberleigh A et al. (2018) Microbial Transplantation With Human Gut Commensals Containing CutC Is Sufficient to Transmit Enhanced Platelet Reactivity and Thrombosis Potential. Circ Res 123:1164-1176
Guo, Chun-Jun; Chang, Fang-Yuan; Wyche, Thomas P et al. (2017) Discovery of Reactive Microbiota-Derived Metabolites that Inhibit Host Proteases. Cell 168:517-526.e18
Dodd, Dylan; Spitzer, Matthew H; Van Treuren, William et al. (2017) A gut bacterial pathway metabolizes aromatic amino acids into nine circulating metabolites. Nature 551:648-652